Evidence map›Paper›PMID 42533032›Full record

ArticleLeukemia2026

Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppression.

C D'Souza, Niko Thio, Ruiqing Zhu, Harini DeSilva, Maria Mempin, Luciano Martelotto, Timothy Semple, Ella Thompson, Stephen Lade, Mark Magnusson and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

C D'SouzaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-2257-6388
Niko ThioCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Ruiqing ZhuCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0009-0000-4386-1327
Harini DeSilvaCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Maria MempinSurgical Infection Research Group, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, 2109, Australia.
Luciano MartelottoAustralia Single Cell Innovation Lab, University of Melbourne, Melbourne, VIC, Australia.
Timothy SempleGenomics Core facility, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Ella ThompsonSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-5206-5111
Stephen LadePathology Department, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Mark MagnussonSchool of Medicine and Dentistry, Griffith University, Southport, Qld, 4222, Australia.ORCID http://orcid.org/0000-0001-5777-8284
Nicholas HousemanDepartment of Surgery, Cabrini Hospital, Monash University, Clayton, VIC, Australia.
Simon OverstallDepartment of Plastic surgery, Cabrini hospital, Monash Health, Clayton, VIC, Australia.
Heather ThorneKConFab, Kathleen Cuningham Foundation Consortium for research into Familial Breast Cancer, Parkville, Australia.
Anand DevaSurgical Infection Research Group, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, 2109, Australia.
Carrie van der WeydenSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Piers BlomberySir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-9902-0022
H Miles PrinceSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. miles.prince@petermac.org.ORCID http://orcid.org/0000-0002-0058-2448
Paul J NeesonCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. paul.neeson@petermac.org.ORCID http://orcid.org/0000-0002-2729-5887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T cell lymphoma in women with textured implants. Little is known about the cell of origin (COO) and whether the tumour immune microenvironment (TIME) is critical for BIA-ALCL survival. Single-cell RNA sequencing revealed BIA-ALCL cells were heterogeneous with unique gene profiles per patient and signature genes BATF3, SERPINS, TNFSFR8, and IL2RA. The COO is a CD4

Indexed as

Breast ImplantsLymphoma, Large-Cell, AnaplasticCD8-Positive T-LymphocytesCytokinesFemaleHumansTumor MicroenvironmentCytokines

Identifiers

PMID42533032
PMCPMC13612225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.